A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501508-82-00

Acronym

IMMU-132-15

Enrollment

Registered

2023-02-01

Start date

2023-08-23

Completion date

Unknown

Last updated

2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026